Optimizing phosphate control with sucroferric oxyhydroxide in CKD
26 Jul 2025
byProf. Li Zuo, Peking University People's Hospital, Beijing, China
Hyperphosphataemia leads to the development of chronic kidney disease–mineral and bone disorder (CKD–MBD), which increases morbidity and mortality in patients with CKD. Aside from dietary restrictions and adequate haemodialysis, phosphate binders play a crucial role in hyperphosphataemia management. At an industry-sponsored symposium during the 29th Hong Kong Medical Forum, Professor Li Zuo of the Peking University People's Hospital in Beijing, China, discussed the advantages of sucroferric oxyhydroxide (SO; Velphoro®, Rxilient) vs other phosphate binders, highlighting its high phosphate-binding capacity, reduced pill burden, and potential benefits for longterm disease control and adherence in patients with CKD–MBD.
